Bangalore-based Hanugen Therapeutics is a biopharmaceutical company focused on developing oligonucleotide-based therapeutics.

Basic Information

Hanugen Therapeutics is a biopharmaceutical company created to deliver advances in oligonucleotide-based medicines to the rare disease community beyond the development of meaningful therapies. The Bangalore-based platform strives to use the power of science to improve the lives of people affected by rare diseases. The company’s novel chemistries enable them to address specific genetic diseases by altering the RNA transcription process and thereby modifying protein structure. The company’s primary goal is to develop new therapies that make a meaningful difference in the lives of patients and their families. The company also focuses on scientific innovation and on unmet medical needs including underserved patient populations with neglected, infectious and other diseases. See more

Legal Name

:

Hanugen Therapeutics Private Limited

Headquarters

:

Bengaluru, Karnataka, India

Business Model

:

B2C, 

B2B 

Founding Date

:

2017

No. of Employees

:

<10

Core Team

:
1.

Arun Shastry

Co-Founder & CSO

2.

Ravdeep Singh Anand

Co-Founder & CEO

3.

Manjula M

Co-Founder & CAO

Timeline
2017
true
Feb | Company Incorporation
Hanugen Therapeutics was established to provide high quality oligonucleotides.
May | Awards
IDEA2POC (ELEVATE) Winner 2018 KBITS GOK.
2018
Mar | Awards
Biotechnology Ignition Grant (BIG) Winner 2018 C-CAMP BIRAC
true

See More

Target Market

B2B

We specialize in modified oligos, fluorescent probes, long oligos and large scale oligo synthesis. The more modifications that are present in an oligo, and the longer the sequence, the more demanding the synthesis and purification.

Client Segment

:

BioTech/BioPharmaceutical, HealthTech / MedTech / Healthcare, Life Sciences, Services

Target Companies

:

Startup, Small Enterprise, Medium Enterprise, Large Enterprise

Target Geography

:

India, Global

B2C

Hanugen Therapeutics is interested in establishing partnerships with companies and organisations with complementary interests. In the past, such partnerships with have been critical in the growth of several large biotech companies.

User Age

:

Less than 18

User Income

:

Lower Income, Lower-middle Income, Upper-middle Income, High Income